Stockreport

Annovis Bio To Continue Alzheimer's Disease Clinical Trials [Seeking Alpha]

Annovis Bio, Inc.  (ANVS) 
PDF Follow Play 8min Summary In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70 [Read more]